N2OFF Rebrands to Nexentis Technologies, Pivoting to AI-Driven Biotech with New Ticker NXTS
NITO is trading near its 52-week low of $0.77 (14% above the low).
Summary
N2OFF, Inc. announced a corporate rebranding to Nexentis Technologies Inc. and a new Nasdaq ticker, NXTS, effective February 26, 2026, signaling a strategic pivot to an AI and data-driven computational biotech platform.
Key Events · Corporate Governance and Compliance · NITO
-
Corporate Rebranding
The company's name will change from N2OFF, Inc. to Nexentis Technologies Inc., effective February 26, 2026.
-
New Ticker Symbol
The trading symbol on the Nasdaq Capital Market will change from 'NITO' to 'NXTS', effective February 26, 2026.
-
Strategic Business Pivot
The rebranding reflects a strategic transformation into an innovative AI and data-driven computational biotech company, focusing on mitochondrial biology, precision oncology, and inflammatory metabolic diseases.
-
Integration of MitoCareX
This strategic shift is built upon the integration and scaling of MitoCareX Bio Ltd., now a wholly-owned subsidiary, which brings a proprietary discovery engine targeting mitochondrial SLC25 carrier family.
Analysis · NITO · Industrial Applications And Services
N2OFF, Inc.'s rebranding to Nexentis Technologies Inc. and change of ticker to NXTS signifies a complete strategic pivot for the company. This move formalizes its transformation into an AI and data-driven computational biotech platform, focusing on mitochondrial biology, precision oncology, and inflammatory metabolic diseases. This strategic shift follows the acquisition of MitoCareX Bio Ltd. and aligns with the previously disclosed divestment of its Save Foods Ltd. stake, fundamentally redefining the company's core business and future direction. For a micro-cap company, such a comprehensive re-orientation is a highly material event, signaling a new investment thesis.
At the time of this filing, NITO was trading at $0.88 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $0.77 to $29.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.